基本信息来源于合作网站,原文需代理用户跳转至来源网站获取       
摘要:
AIM:To identify non-quinazoline kinase inhibitors effective against drug resistant mutants of epidermal growth factor receptor(EGFR).METHODS:A kinase inhibitor library was subjected to screening for specific inhibition pertaining to the in vitro kinase activation of EGFR with the gatekeeper mutation T790 M,which is resistant to small molecular weight tyrosine kinase inhibitors(TKIs) for EGFR in nonsmall cell lung cancers(NSCLCs). This inhibitory effect was confirmed by measuring autophosphorylation of EGFR T790M/L858 R in NCI-H1975 cells,an NSCLC cell line harboring the gatekeeper mutation. The effects of a candidate compound,Janus kinase 3(JAK3) inhibitor Ⅵ,on cell proliferation were evaluated using the MTT assay and were compared between T790M-positive and-negative lung cancer cell lines. JAK3 inhibitor Ⅵ was modeled into the ATP-binding pocket of EGFR T790M/L858 R. Potential physical interactions between the compound and kinase domains of wild-type(WT) or mutant EGFRs or JAK3 were estimated by calculating binding energy. The gatekeeper residues of EGFRs and JAKs were aligned to discuss the similarities among EGFR T790 M and JAKs. RESULTS:We found that JAK3 inhibitor Ⅵ,a known inhibitor for JAK3 tyrosine kinase,selectively inhibits EGFR T790M/L858 R,but has weaker inhibitory effects on the WT EGFR in vitro. JAK3 inhibitor Ⅵ also specifically reduced autophosphorylation of EGFR T790M/L858 R in NCI-H1975 cells upon EGF stimulation,but did not show the inhibitory effect on WT EGFR in A431 cells. Furthermore,JAK3 inhibitor Ⅵ suppressed the proliferationof NCI-H1975 cells,but showed limited inhibitory effects on the WT EGFR-expressing cell lines A431 and A549.A docking simulation between JAK3 inhibitor Ⅵ and the ATP-binding pocket of EGFR T790M/L858 R predicted a potential binding status with hydrogen bonds. Estimated binding energy of JAK3 inhibitor Ⅵ to EGFR T790M/L858 R was more stable than its binding energy to the WT EGFR. Amino acid sequence alignments revealed that the gatekeeper residues of JAK
推荐文章
非小细胞肺癌T790M基因突变研究进展
肺肿瘤
表皮生长因子受体
T790M
酪氨酸激酶抑制剂
原发T790M突变非小细胞肺癌研究进展
肺肿瘤
表皮生长因子受体
T790M
非小细胞肺癌患者T790M突变致酪氨酸激酶的耐药机制及用药策略
非小细胞肺癌
T790M
表皮生长因子受体
酪氨酸激酶抑制剂耐药
TKI耐药后针对T790M突变治疗
表皮生长因子受体
酪氨酸激酶抑制剂
肺肿瘤
TKI耐药
T790M
阿法替尼
Dacomitinib
厄洛替尼
吉非替尼
内容分析
关键词云
关键词热度
相关文献总数  
(/次)
(/年)
文献信息
篇名 JAK3 inhibitor Ⅵ is a mutant specific inhibitor for epidermal growth factor receptor with the gatekeeper mutation T790M
来源期刊 世界生物化学杂志:英文版(电子版) 学科 医学
关键词 EPIDERMAL growth factor receptor TYROSINE KINASE i
年,卷(期) 2015,(4) 所属期刊栏目
研究方向 页码范围 409-418
页数 10页 分类号 R734.2
字数 语种
DOI
五维指标
传播情况
(/次)
(/年)
引文网络
引文网络
二级参考文献  (0)
共引文献  (0)
参考文献  (13)
节点文献
引证文献  (0)
同被引文献  (0)
二级引证文献  (0)
2015(0)
  • 参考文献(0)
  • 二级参考文献(0)
  • 引证文献(0)
  • 二级引证文献(0)
研究主题发展历程
节点文献
EPIDERMAL
growth
factor
receptor
TYROSINE
KINASE
i
研究起点
研究来源
研究分支
研究去脉
引文网络交叉学科
相关学者/机构
期刊影响力
世界生物化学杂志:英文版(电子版)
季刊
1949-8454
北京市朝阳区东四环中路62号楼远洋国际中
出版文献量(篇)
391
总下载数(次)
0
论文1v1指导